Compare Capri Holdings Ltd (CPRI) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Medpace Holdings Inc — how do they compare? Capri Holdings Ltd trades at $14.83 (market cap $1.67B), while Medpace Holdings Inc trades at $614.63 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 10.1× Capri Holdings Ltd's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Medpace Holdings Inc for 14 Days on average.
| CPRI | MEDP | |
|---|---|---|
Market Cap | $1.67B | $16.82B |
Volume | 3,722,279 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $630.19 |
52-Week Low | $12.71 | $393.42 |
Typical Hold Time | 41 Days | 14 Days |
Enterprise Value | $2.95B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.83, up 2.7% with bullish technical signals and recent earnings beats. The stock shows strong momentum with three consecutive quarterly EPS beats and positive analyst sentiment (44% buy ratings). However, fundamentals reveal challenges with declining revenue ($4.44B in 2025 vs $5.7B in 2022) and negative net income (-$1.18B), though profitability metrics show improvement potential with 62.7% gross margins.
The outlook balances attractive valuation (P/S 0.51) against turnaround execution risks. Upside exists if brand revitalization succeeds, but investors face headwinds from Michael Kors weakness and competitive pressures. The consensus price target of $20.57 suggests 39% potential upside if recovery gains traction in H2 2026 as management projects.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
